Lv1
20 积分 2023-01-28 加入
Bioanalytical challenges and solutions for immunogenicity evaluation of bispecific antibody therapeutics
3个月前
已完结
Characterization of Anti-CD3 Antibodies in Clinically Available Bispecific T Cell Engagers
1年前
已关闭
Human kallikrein 2: A novel lineage-specific surface target in prostate cancer
1年前
已完结
Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy
1年前
已完结
Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T‐Cell Engager, in Prostate Cancer Patients
1年前
已完结
Discovery and Phase 1 study of a novel monoclonal antibody against human IL-1β for the treatment of IL-1β-mediated diseases
1年前
已完结
皖公网安备34019202002308
